L. Grip

Publication List Details

Period

1991 - 2009

Number

17

Co-Authors

Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease (2003)

Oldgren, J, Wallentin, L, Grip, L, Linder, R, Nørgaard, B.L, Siegbahn, A

Aim Unstable coronary artery disease (CAD) is a multifactorial disease involving both thrombotic and inflammatory processes. We have assessed the time-course and the influence of thrombin inhibitors...

Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial (2002)

Stables, RH, Booth, J, Erbel, R, Wahrborg, P, Lubsen, J, ...

Background Results of trials, comparing percutaneous transluminal coronary angioplasty (PTCA) with coronary artery bypass grafting (CABG), indicate that rates of death or myocardial infarction are...

Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial (2002)

Holmes, D.R. Jr, Granett, J.R., Popma, J., Serruys, P.W., Fitzgerald, P., Fischman, D., ...

BACKGROUND: Restenosis after percutaneous coronary intervention (PCI) is a major problem affecting 15% to 30% of patients after stent placement. No oral agent has shown a beneficial effect on...

The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease (1999)

Linder, R., Oldgren, J., Egberg, N., Grip, L., Larson, G., Siegbahn, A., ...

Aim This study evaluated a novel specific thrombin inhibitor, inogatran, in comparison with unfractionated heparin, with regard to markers for coagulation activity in patients with unstable coronary...

The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points (1999)

Näslund, U., Grip, L., Fischer-Hansen, J., Gundersen, T., Lehto, S., Wallentin, L.

Background A multicentre study permits rapid recruitment of a large number of patients. However, there is a risk of heterogeneities in end-point evaluations, as complex definitions of criteria are...

Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease (1999)

Oldgren, J., Linder, R., Grip, L., Siegbahn, A., Wallentin, L.

Aims Direct thrombin inhibitors have failed to prove superiority over unfractionated heparin in several clinical trials of unstable coronary artery disease. We have investigated the relationship...

Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris: A controlled randomized double-blind pilot study (1997)

Grip, L., Blombäck, M., Egberg, N., Olsson, Å., Svane, B., Velander, M.

Background Thrombin activation may be a higher risk for complications and restenosis after percutaneous transluminal coronary angioplasty in unstable patients than in patients with stable angina...

Secondary preventive potential of lipid-lowering drugs: The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) (1996)

De Faire, U., Grip, L., Nilsson, J., Svane, B., Hamsten, A.

Current experience from coronary angiographic trials using different treatment regimens such as lifestyle changes, resins, nicotinic acid and statins, shows that progression of atheroma can be...

Late thrombolysis followed by antithrombotic treatment in acute myocardial infarction: effect of therapy evaluated with thallium-201 SPECT (1993)

GRIP, L., BONE, D., HOLMGREN, A., RYDÉN, L.

Perfusion abnormalities and infarct size evaluated by thallium-201 SPECT after late thrombolysis followed by anti-thrombotic treatment in acute myocardial infarction were studied in 111 patients....

Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients (1991)

GRIP, L., BLOMBÄCK, M., SCHULMAN, S.

Nine out of 47 (19%) patients on chronic anticoagulation with warfarin, as secondary prophylaxis after myocardial infarction, initially treated with streptokinase, had thromboembolic...

Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients (1991)

GRIP, L., BLOMBÄCK, M., SCHULMAN, S.

Nine out of 47 (19%) patients on chronic anticoagulation with warfarin, as secondary prophylaxis after myocardial infarction, initially treated with streptokinase, had thromboembolic...

Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction

Montalescot, G, Andersen, H R, Antoniucci, D, Betriu, A, De Boer, M J, Grip, L, ...

Little information is currently available from the various societies of cardiology on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Since primary PCI is the...

Long term risk stratification of patients with acute coronary syndromes: characteristics of troponin T testing and continuous ST segment monitoring

Nørgaard, B L, Andersen, K, Thygesen, K, Ravkilde, J, Abrahamsson, P, Grip, L, ...

Objective: To examine the long term prognostic characteristics of troponin T testing and continuous multi-lead ST segment monitoring in combination with clinical and 12 lead ECG risk indicators in...